Abstract:Introduction Diabetes and cancer are commonly linked together. The possible links include insulin resistance, hyperinsulinemia, hyperglycemia, oxidative stress, and chronic inflammation. These are factors that have potential promoting effects on the progression of cancer in many ways. Measurement of prostate-specific antigen (PSA) is widely applied for early detection of prostate cancer. However, several factors influence serum PSA levels in men including age, benign prostatic hyperplasia, prostatitis, and body mass index (BMI). The risk of several malignancies is increased in diabetes but the risk of prostate carcinoma in diabetic patients is reduced secondary to lowering of testosterone levels during the state of hyperinsulinemia. A negative association between serum PSA levels and metformin use is also an explanation of low cancer prostate incidence with diabetes. Objective The study aims to evaluate the PSA levels in diabetic patients with poor glycemic control i.e., glycated hemoglobin (HbA1c) ≥ 7%) vs good glycemic control (HbA1c < 7%). Materials and methods Samples of PSA in diabetic patients collected in the Department of Biochemistry at Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, were included. The observational study was carried out on clinically diagnosed 318 cases of diabetes attending both the outpatient and inpatient Department, IGIMS, Patna. Six ml venous blood samples were collected from patients after obtaining informed consent and ethical clearance. Patient details regarding age, complete clinical details, and general physical examinations were recorded. Serum levels of PSA, fasting plasma glucose (FPG) and HbA1c were analyzed and values were compared. The serum level of PSA was estimated by the chemiluminescent immunoassay (CLIA) method on an automated immunoassay analyzer in the Department of Biochemistry, maintaining all the quality control precautions using a control, calibrator, and reagent kit. HbA1c estimation was by chromatography technique. Fasting plasma glucose was estimated using the hexokinase method on an automated chemistry analyzer. Statistical analyses were performed using SPSS software, version 16.0 (SPSS Inc., Chicago). The median and interquartile range were calculated for numerical variables. Covariance analysis was used in the comparisons among groups. The Mann-Whitney U test was applied to detect the comparison between the two groups. Significance was determined by the P value. P value<0.05 was considered significant. Result Serum PSA value was found to be higher in (the good glycemic control group) with a median of 0.99 with an interquartile range of 3.14, than in (the bad glycemic control group) with a median of 0.49 with an interquartile range of 3.9, and the difference is statistically significant. The difference is also statistically significant in the subgroup (i) with PSA value <4 ng/ml. In subgroups (ii) and (iii), PSA values 4 ng/ml-8 ng/ml and PSA values >8 ng/ml respectively, no significant differences were found. Conclusion It was found that serum prostate-specific antigen levels have been lower in diabetic patients with poor glycemic control than in good glycemic control. Future studies with a larger sample size and detailed information on diabetes duration and management are recommended.

Serum glycosylated hemoglobin and prostate cancer risk: Results from a systematic review and dose-response meta-analysis

Diabetes Mellitus and Prostate Cancer Risk of Different Grade or Stage: A Systematic Review and Meta-Analysis

Serum uric acid and prostate cancer: findings from the NHANES (2007–2020)

Diabetes Mellitus and Prostate Cancer Risk—A Systematic Review and Meta-Analysis

Diabetes mellitus reduces prostate cancer risk - no function of age at diagnosis or duration of disease.

Association of Diabetes Mellitus with Prostate Cancer Grade and Prostate-Specific Antigen in Chinese Biopsy Population

The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data

Glycosylated Hemoglobin Levels And Clinical Outcomes In Nondiabetic Patients With Coronary Artery Disease A Meta-Analysis

Poor Glycemic Control Affecting Screening of Prostate Carcinoma

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Effect Of Metformin On Cancer Risk And Treatment Outcome Of Prostate Cancer: A Meta-Analysis Of Epidemiological Observational Studies

Elevated HbA1c Levels Are Associated with a Risk of Pancreatic Cancer: A Case-Control Study

Association between glycated hemoglobin and risk of all‐cause mortality in community patients with type 2 diabetes: A prospective cohort study

Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies

Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis

Effects of Diabetes Mellitus and Metformin Administration on Prostate Cancer Detection at Biopsy among Chinese Men: a Case-Control Study.

Plasma total cholesterol concentration and risk of higher‐grade prostate cancer: A nested case‐control study and a dose‐response meta‐analysis

The causal effect of serum amino acids on the risk of prostate cancer: a two-sample mendelian randomization study

The U-Shape Relationship Between Glycated Hemoglobin Level and Long-Term All-Cause Mortality Among Patients With Coronary Artery Disease

Glycated Hemoglobin and All-Cause and Cause-Specific Mortality among Adults with and Without Diabetes.

Association of Measures of Glucose Metabolism with Colorectal Cancer Risk in Older Chinese: A 13-Year Follow-up of the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy and Meta-Analysis